Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 5
Submit an article Journal homepage
552
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales

Jason TayTom Baker Cancer Center, University of Calgary, Calgary, AB, Canada; View further author information
,
Ravi VijDivision of Oncology, Washington University School of Medicine, Saint Louis, MO, USA; View further author information
,
Maxim NorkinDepartment of Medicine/Division of Hematology Oncology, University of Florida, Gainesville, FL, USA; View further author information
,
Francis BuadiDivision of Hematology, Mayo Clinic, Rochester, MN, USA; View further author information
,
Tamila L. Kindwall-KellerDivision of Hematology/Oncology, University of Virginia, Charlottesville, VA, USA; View further author information
,
Jenna S. RobertsAdelphi Real World, Macclesfield, UK; Correspondence[email protected]
View further author information
,
Darrell J. WhiteQueen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada; View further author information
,
Robert P. WoodAdelphi Real World, Macclesfield, UK; View further author information
,
Sophee E. Blanthorn-HazellAdelphi Real World, Macclesfield, UK; View further author information
,
Adriana C. RossiDivision of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA; View further author information
,
Sujith DhanasiriCelgene International, Boudry, Switzerland; View further author information
,
Faiza ZafarCelgene Corporation, Summit, NJ, USA; View further author information
,
Kim NewhouseCelgene Inc, Mississauga, ON, Canada; View further author information
&
Arleigh R. McCurdyDivision of Hematology, The Ottawa Hospital and The University of Ottawa, Ottawa, ON, CanadaView further author information
 show all
Pages 1275-1282 | Received 29 Mar 2018, Accepted 09 Sep 2018, Published online: 31 Oct 2018

References

  • Sengsayadeth S, Malard F, Savani BN, et al. Post-transplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J. 2017;7:e545.
  • Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9:52.
  • Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128.
  • Kagoya Y, Nannya Y, Kurokawa M. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res. 2012;36:1016–1021.
  • Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119:7–15.
  • McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3289.
  • Kvam AK, Waage A. Health-related quality of life in patients with multiple myeloma-does it matter? Haematologica. 2015;100:704–705.
  • Gadó K, Domján G. Quality of life issues of patients with multiple myeloma. In: Hajek R, editor. Multiple myeloma. IntechOpen; 2013. DOI: 10.5772/55625. Available from: https://www.intechopen.com/books/multiple-myeloma-a-quick-reflection-on-the-fast-progress/quality-of-life-issues-of-patients-with-multiple-myeloma
  • Food and Drug Administration. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. (2007). Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. (Accessed: 3rd August 2017)
  • Johnsen AT, Tholstrup D, Petersen MA, et al. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009;83:139–148.
  • Dimopoulos MA, Delforge M, Hájek R, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98:784–788.
  • Sirohi B, Powles R, Lawrence D, et al. An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b. J Eur Soc Med Oncol. 2007;18:1388–1394.
  • Nielsen LK, Jarden M, Andersen CL, et al. A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol. 2017;99:3–17.
  • Shah GL, Giralt SA. Recommend upfront consolidation with high-dose melphalan and autologous stem cell support. Semin Oncol. 2016;43:707–708.
  • Abonour R, Jiang H, Masih-Khan E, et al. Health-related quality of life of patients with newly diagnosed multiple myeloma receiving any or lenalidomide maintenance after autologous stem cell transplant in the Connect® MM Disease Registry. Blood. 2016;128:537–537.
  • Osborne TR, Ramsenthaler C, Siegert RJ, et al. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol. 2012;89:437–457.
  • Yang C, Durie BGM, Jagannath S, et al. Tolerability and efficacy of post-transplant lenalidomide maintenance therapy in multiple myeloma: a real world single centre experience. Blood. 2017;130:3462–3462.
  • Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101–119.
  • Germany RF, Giagounidis A, Goldschmidt H, Heinsch M, Rummel MJ, Kröger N, Boquoi A, Lopez D, Hauck K, Gerrlich C, Baier J, Liesenjohann S, Boelke E, Mai E, Aul C, Strapatsas J, Dienst A, Kondakci M, Haas R, Kobbe G. University Hospital Duesseldorf, Dept of Hematology, Oncology and clinical Immunology, Duesseldorf, Germany; Marien Hospital Düsseldorf, Düsseldorf, Germany; Department of Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany; Helios St Johannis Hospital Duisburg, Duisburg, Germany; Department of Haematology and Oncology, Justus-Liebig Universität, Giessen, Germany; Department for Stem Cell Transplantation, University Cancer Center, Hamburg, Germany; University of Duesseldorf, Duesseldorf. Welcome. Meeting Abstracts Available at: index.html. (Accessed: 17th July 2018)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.